**Suppl. Table 3** Laboratory parameters in DILI patients with ANA† titers ≥ 1:400 vs. undetectable or low ANA titers at the onset of disease

|  |  |  |  |
| --- | --- | --- | --- |
|  | **ANA ≥ 1:400****(n=41; 28 %)** | **ANA < 1:400****(n=103; 72 %)** | **p** |
| **ALT ‡ onset 1** | 27.1 (1.1-145.5) | 21.3 (0.4-116.5) | 0.16 |
| **AST § onset 1** | 19.7 (1.0-104.0) | 12.2 (0.5-202.2) | **0.05 \*** |
| **ALP ¶ onset 1** | 1.8 (0.4-3.8) | 1.5 (0.4-14.5) | 0.34 |
| **TB †† onset 1** | 6.5 (0.5-41.5) | 2.1 (0.1-48.8) | **0.05 \*** |
| **INR ‡‡ onset**  | 1.1 (0.9-3.7) | 1.1 (0.8-5.0) | 0.74 |
| **R-Ratio onset**  | 19.3 (0.3-88.1) | 15.1 (0.3-164.6) | 0.41 |
| **Latency between initiation of drug treatment and onset of liver injury (days)** | 57 (1-1589) | 53 (1-1987) | 0.79 |

Values are stated as median (range). 1 laboratory values are given as times ULN (upper limit of normal); † ANA:antinuclear antibodies; ‡ ALT: alanine aminotransferase; **§** AST: aspartate aminotransferase; ¶ ALP: alkaline phosphatase; ††TB: total bilirubin;‡‡ INR:international normalized ratio. \* shows a statistical significance (p≤0.05).